Basel Medical Group Ltd. revenue rises 12.6% to S$11.3 million for fiscal 2025

Reuters11-18
<a href="https://laohu8.com/S/BMGL">Basel Medical Group Ltd</a>. revenue rises 12.6% to S$11.3 million for fiscal 2025

Basel Medical Group Ltd. reported revenue of S$11.3 million (US$8.9 million) for the fiscal year ended June 30, 2025, an increase of 12.6% from S$10.1 million in the previous year. The revenue growth was mainly due to the acquisition of a general practitioners clinic group, which contributed S$895,362, and a 3.7% increase in revenue from its orthopedic specialist clinic at Gleneagles. Net cash used in operating activities was S$3.4 million, while net cash generated from financing activities totaled S$13.3 million. Cash and cash equivalents at year-end stood at S$3.0 million (US$2.3 million). The company's directors stated that available working capital is sufficient to meet present requirements for at least 12 months after the period end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basel Medical Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-023940), on November 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment